Summary
- Main use
- Improvement of nutritional status by providing calories and essential fatty acids to patients receiving parenteral nutrition
- Who receives it
- Adults · Children
- Adult administration
- Route of administration: Intravenous When administered with glucose and amino acids, select a central or peripheral vein according to the osmolality of the final admixture. In rare cases, when administered alone as a supplement to oral or enteral nutrition, it may be administered through a peripheral vein. Dose: The dose is determined based on the patient's energy expenditure, clinical condition, body weight, metabolic capacity, and additional calories provided orally and through the gastrointestinal tract. Therefore, the bag size should be determined individually for each patient. Adults: Administer 1 g to a maximum of 2 g of lipid/kg body weight/day. At the start of administration, infuse slowly; during the first 10 minutes, do not exceed 0.1 g of lipid or 0.5ml (10 drops) per minute, then gradually increase the rate to reach the appropriate rate after 30 minutes. Do not exceed 0.15g/kg/hour of lipid (0.75ml/kg/hour). Adults (per unit of body weight) (e.g.) Adult weighing 70kg Usual lipid dose 1~2g/kg/day 70~140g/day Volume of Clinoleic 20% to be administered 5~10ml/kg/day 350~700ml/day Use as a nutritional admixture with glucose and amino acids Before administration to the patient, confirm the compatibility of the ingredients and the stability of the admixture. Prepare the admixture by gently mixing under strictly aseptic conditions. Fat separation from the emulsion can be identified visually by the presence of yellow droplets or particles. An infusion time of 12-24 hours is recommended for parenteral nutrition solutions, depending on the clinical condition. Parenteral nutrition may be continued for as long as needed, depending on the patient's clinical condition. However, if long-term administration is required, the risks and benefits should be regularly evaluated, and assessment for resumption of oral and enteral nutrition is particularly necessary. The infusion rate should be considered according to the dose, daily dose, and duration of infusion.
- Child administration
- When administering to infants and newborns under 2 years of age, protect this medicine (the container and infusion set) from light until the end of administration. Pediatric patients: Infuse continuously over 24 hours. The daily dose should not exceed 3g/kg body weight, and the infusion rate should not exceed 0.15g/kg body weight/h. The daily dose should be increased gradually during the first week of administration. Premature and low-birth-weight infants: Use is restricted to premature infants with a gestational age of 28 weeks or more. Infuse continuously over 24 hours. The initial daily dose is 0.5 - 1.0g of lipid/kg body weight; the dose may be increased by 0.5 - 1.0 g of lipid/kg body weight every 24 hours until a daily dose of 2.0g of lipid/kg body weight is reached.
Ingredients
- Importer
- .
Efficacy & effects
Improvement of nutritional status by providing calories and essential fatty acids to patients receiving parenteral nutrition
View approved original textHide original text
This medication effectively provides calories and essential fatty acids for patients in need of non-oral nutritional support, thereby improving nutritional status.
How it is given
Adult administration
Route of administration: Intravenous When administered with glucose and amino acids, select a central or peripheral vein according to the osmolality of the final admixture. In rare cases, when administered alone as a supplement to oral or enteral nutrition, it may be administered through a peripheral vein. Dose: The dose is determined based on the patient's energy expenditure, clinical condition, body weight, metabolic capacity, and additional calories provided orally and through the gastrointestinal tract. Therefore, the bag size should be determined individually for each patient. Adults: Administer 1 g to a maximum of 2 g of lipid/kg body weight/day. At the start of administration, infuse slowly; during the first 10 minutes, do not exceed 0.1 g of lipid or 0.5ml (10 drops) per minute, then gradually increase the rate to reach the appropriate rate after 30 minutes. Do not exceed 0.15g/kg/hour of lipid (0.75ml/kg/hour). Adults (per unit of body weight) (e.g.) Adult weighing 70kg Usual lipid dose 1~2g/kg/day 70~140g/day Volume of Clinoleic 20% to be administered 5~10ml/kg/day 350~700ml/day Use as a nutritional admixture with glucose and amino acids Before administration to the patient, confirm the compatibility of the ingredients and the stability of the admixture. Prepare the admixture by gently mixing under strictly aseptic conditions. Fat separation from the emulsion can be identified visually by the presence of yellow droplets or particles. An infusion time of 12-24 hours is recommended for parenteral nutrition solutions, depending on the clinical condition. Parenteral nutrition may be continued for as long as needed, depending on the patient's clinical condition. However, if long-term administration is required, the risks and benefits should be regularly evaluated, and assessment for resumption of oral and enteral nutrition is particularly necessary. The infusion rate should be considered according to the dose, daily dose, and duration of infusion.
Child administration
When administering to infants and newborns under 2 years of age, protect this medicine (the container and infusion set) from light until the end of administration. Pediatric patients: Infuse continuously over 24 hours. The daily dose should not exceed 3g/kg body weight, and the infusion rate should not exceed 0.15g/kg body weight/h. The daily dose should be increased gradually during the first week of administration. Premature and low-birth-weight infants: Use is restricted to premature infants with a gestational age of 28 weeks or more. Infuse continuously over 24 hours. The initial daily dose is 0.5 - 1.0g of lipid/kg body weight; the dose may be increased by 0.5 - 1.0 g of lipid/kg body weight every 24 hours until a daily dose of 2.0g of lipid/kg body weight is reached.
Precautions
Care should be taken when administering this drug to premature infants and low-birth-weight infants as it may increase serum free fatty acid levels. Patients with allergies, especially those sensitive to egg, peanut, and soybean proteins, should not use this medication. This drug should not be administered to patients with metabolic disorders, severe dyslipidemia, acute pancreatitis, myocardial infarction, or metabolic instability. Rarely, allergic reactions may occur upon administration of this medication, so if symptoms such as sweating, chills, headache, or apnea appear, use should be immediately discontinued. Long-term use may lead to liver dysfunction, thrombocytopenia, hyperglycemia, and hypertriglyceridemia, hence regular check-ups are required. As the fat overload syndrome may occur, appropriate dosing should be adhered to, and the patient's condition should be closely monitored. If serious hypersensitivity reactions such as anaphylaxis occur, administration must be immediately stopped, and appropriate measures taken. Serum triglyceride levels should be checked daily and must not exceed 3 mmol/L. During non-oral nutritional therapy, liver function tests, blood sugar, electrolytes, and coagulation status should be routinely monitored. Patients with excessive fluid or electrolyte imbalances or metabolic disorders should correct their condition before administering this drug. Fat emulsion should be administered along with carbohydrates and amino acids to prevent metabolic acidosis. In patients with acute kidney dysfunction, pulmonary edema, or heart failure, fluid balance should be carefully managed. When administering to neonates or children, careful management under specialist supervision is required, particularly in cases of hyperbilirubinemia, where bilirubin levels must be monitored closely. There is a risk of infection and sepsis associated with intravenous infusion, thus aseptic techniques and catheter management should be strictly followed. Patients with liver failure are at risk of deteriorating liver function; hence frequent clinical and laboratory tests should be conducted considering the possibility of liver disease associated with non-oral nutrition. Patients with blood coagulation disorders or anemia should closely observe blood counts and coagulation factors and daily check for symptoms of thrombophlebitis at the intravenous injection site. In severely malnourished patients, refeeding syndrome may occur when nutrition is resumed, so nutrition should be gradually increased with careful monitoring. When administering to neonates and infants under the age of 2, exposure to light should be avoided. It is important to verify compatibility and carefully mix this medication when combined with other drugs and to properly mix before combining. Except in special cases, it is safest for women during pregnancy or breastfeeding not to use this medication. After administration, lipid components may affect blood test results, thus caution is advised. In cases of overdose, symptoms such as fever, vomiting, liver dysfunction, and blood coagulation disorders may occur, and administration should be stopped or reduced as necessary. This medication is for single use; check the packaging and homogeneity of the solution before use. After opening, use immediately, do not reuse leftover medication, and dispose of used equipment properly. To prevent air embolism during administration, any residual gas in the injection solution must be completely removed, and continuous connection should be avoided. Store this medication in a sealed container to prevent contact with air. Additionally, avoid freezing and maintain the temperature below 25 degrees Celsius. It is important to store it away from direct sunlight.
Side effects
- Allergic reactions
- sweating
- chills
- headache
- apnea
- elevated alkaline phosphatase
- elevated transaminases
- elevated bilirubin
- hepatomegaly
- jaundice
Show 27 moreCollapse
- thrombocytopenia
- hypertriglyceridemia
- increased blood glucose levels
- nausea
- vomiting
- abdominal distension
- abdominal pain
- upper abdominal discomfort
- diarrhea
- cholestasis
- urticaria
- pruritus
- chills
- decreased mean arterial pressure
- elevated serum bilirubin
- increased conjugated bilirubin
- elevated liver enzymes
- increased serum triglycerides
- decreased INR
- hyperlipidemic syndrome
- fever
- hemodynamic instability
- liver dysfunction
- hepatomegaly or splenomegaly
- coagulopathy
- hyperlipidemia
- hypersensitivity reactions
Not everyone experiences these, and they can vary from person to person.
Storage
This medication should be stored in a sealed container to avoid contact with air. Also, care should be taken to prevent the medication from freezing, maintaining a temperature below 25 degrees Celsius. It is important to store it away from direct sunlight.
Appearance and packaging
Appearance
A colorless, transparent solution in a plastic bag with a unique odor, which is a milky-white homogeneous solution.
Package unit
100, 250, 500ml/bag
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.